The Atriva Management
Rainer Lichtenberger, Ph.D. MBA
More than 30 years management in life science Industry, EVP Merckle/ratiopharm group for BD; Since 16 years CEO/COO experience in several SME, raised € 80 Mn venture funds.
Christian Wallasch, Ph.D.
Seasoned executive management member (COO, CEO) in biopharmaceuticals SME, as Axxima and U3, as well as public companies like Intercell/Valneva. Expert in kinase inhibitors, vaccines development, project management and execution.
Stephan Stenglein, M.D.
Physician trained in Clinical and Molecular Virology with 20 years of accomplishments in pharma, medical device and vaccine development. Previous global management positions with Novartis and AstraZeneca.
Prof. Oliver Planz, Ph.D.
Universität D-Tübingen, Co-inventor of the technology, expert in antiviral research und translational preclinical R&D up to clinical studies. Advises the WHO on antiviral strategies against influenza.
Björn Cochlovius, Ph.D., Assoc. Prof.
VP Business Development
20 years leadership positions in SMEs (Head R&D Affitech, CEO OnTarget) and big pharma (Roche, Otsuka, Abbvie). Working experiences in Europe and Asia. Background in R&D, Business Development, M&A, Financing.